Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE studyHagop M. Kantarjian, Anjali S. Advani, Barbara Sleight et al.|Cancer|2019Cited by 327
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)Nicolaus Kröger, Théo de Witte, Simona Iacobelli et al.|Journal of Clinical Oncology|2017Cited by 248
Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialDomenico Russo, Cyrus Badshah, Michael Henry Schmitt et al.|The Lancet Haematology|2023Cited by 100
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trialElias Jabbour, Hagop Kantarjian, Nicola Gökbuget et al.|Leukemia Research|2019Cited by 52
Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.Elias Jabbour, Hagop M. Kantarjian, Nicola Gökbuget et al.|Journal of Clinical Oncology|2018Cited by 6